Cancer Treatment; New Strategies/New Hopes


Beginning in the early 2000s and based on the better understanding of the biology of cancer, new drugs have been developed that target specific molecular pathway in malignant cells. There has been a significant shift from the development of classic cytotoxic agents toward targeted therapies. Dose limiting toxicities of target therapies are often different. These agents have unique mechanism of action and are very specific for one or several key cellular biologic pathways. Introduction of these agents was
associated with a significant progress in the management of some cancers. A good example is use of tyrosine kinase inhibitor (TKIs) for the treatment of chronic myeloid leukemia. Imatinib was the first one and several other TKIs such as dasatinib, nilotinib, bosutinib and ponatinib have been developed.

No References No References No References
IssueVol 8, No 1 (Winter 2020) QRcode
DOI https://doi.org/10.18502/jpc.v8i1.2739
No Keywords

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Salehifar E, Tavakkoli-Ardakani M. Cancer Treatment; New Strategies/New Hopes. J Pharm Care. 2020;8(1):1-2.